AstraZeneca wins two recommendations, one priority review

AstraZeneca PLC on Monday said it won two recommendations for approval in the EU and one priority review in the US.

AstraZeneca's and Daiichi Sankyo Co Ltd's breast cancer drug Enhertu won strategic priority review in the US for patients with some forms of breast cancer. "Enhertu is a specifically engineered HER2-directed antibody drug conjugate," AstraZeneca, a Cambridge-based pharmaceutical company, explained. HER2 stands for human epidermal growth factor receptor 2, a protein that promotes the growth of cancer cells.